Lung Function Response to 12-week Treatment with Combined Inhalation of Long-acting β2 Agonist and Glucocorticoid According to ADRB2 Polymorphism in Patients with Chronic Obstructive Pulmonary Disease
Authors:
- 29 August 2008
- journal article
- research article
- Published by Springer Nature in Lung
- Vol. 186 (6) , 381-386
Abstract
Recent reports suggest that β2-adrenergic receptor (ADRB2) genotypes are associated with therapeutic responses to β2 agonists in asthmatics. However, few studies have investigated therapeutic responses to β2 agonists in chronic obstructive pulmonary disease (COPD) patients. This study investigated immediate bronchodilator response and lung function responses following a 12-week treatment with a long-acting β2 agonist combined with a steroid inhaler in patients with COPD with various ADRB2 genotypes. One hundred four patients with chronic obstruction were genotyped for codon 16 and 27 polymorphisms of the ADRB2 gene. The immediate bronchodilator response to β2-agonist treatment was evaluated after inhalation of 400 μg salbutamol. In addition, long-term response was evaluated using observed change in spirometric values before and after the treatment with salmeterol (50 μg) combined with fluticasone propionate (500 μg) inhalation twice daily for 12 weeks. In terms of codon 16 variants, the immediate bronchodilator response to salbutamol was 6.4 ± 0.8% (% predicted value) in Arg/Arg patients, 4.9 ± 0.7% in Arg/Gly patients, and 5.8 ± 1.2% in Gly/Gly patients (p = 0.418). The FEV1 changes following the 12-week treatment were 7.0 ± 1.2% in Arg/Arg patients, 3.0 ± 1.5% in Arg/Gly patients, and 7.2 ± 1.2% in Gly/Gly patients (p = 0.229). Similarly, there was no difference between codon 27 variants in terms of immediate bronchodilator response or FEV1 changes after 12 weeks of treatment. We were unable to demonstrate an association between ADRB2 genotype and the effect on lung function of 12-week treatment with combined long-acting β2 agonist and glucocorticoid inhalation or on the immediate bronchodilator response to a short-acting β2 agonist in patients with COPD.Keywords
This publication has 28 references indexed in Scilit:
- Sequence, Haplotype, and Association Analysis of ADRβ2 in a Multiethnic Asthma Case-Control StudyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Corticosteroids and adrenoceptor agonists: The compliments for combination therapy in chronic airways diseasesEuropean Journal of Pharmacology, 2006
- Association between bronchodilating response to short‐acting β‐agonist and non‐synonymous single‐nucleotide polymorphisms of β2‐adrenoceptor geneClinical & Experimental Allergy, 2005
- Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary diseaseThorax, 2005
- Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trialThe Lancet, 2004
- Inhaled Combination Therapy With Long-Acting β 2 -Agonists and Corticosteroids in Stable COPDChest, 2004
- Inhaled Salmeterol/Fluticasone PropionateDrugs, 2004
- Score Tests for Association between Traits and Haplotypes when Linkage Phase Is AmbiguousThe American Journal of Human Genetics, 2002
- The Effect of Common Polymorphisms of the β2-Adrenergic Receptor on Agonist-Mediated Vascular DesensitizationNew England Journal of Medicine, 2001
- Influence of genetic polymorphisms in the ??2-adrenoceptor on desensitization in human lung mast cellsPharmacogenetics, 2000